Signature Bank: Eric Howell To Assume COO Role; Names Stephen Wyremski CFO

Signature Bank (SBNY) said Mark Sigona, Senior Executive Vice President and Chief Operating Officer, will retire, effective June 30, 2021. Eric Howell, Senior Executive Vice President-Corporate and Business Development since 2013, will assume the COO role.

The company also announced that Executive Vice President and Chief Financial Officer Vito Susca will move into the newly created post of EVP and Chief Administrative Officer. Stephen Wyremski, Senior Vice President and Controller since joining the Bank in 2015, will be promoted to Senior Vice President and Chief Financial Officer, effective June 30, 2021.

Peter Quinlan, Executive Vice President and Treasurer, will also retire, effective June 30, 2021. Kevin Hickey, Senior Vice President and Chief Risk Officer for the past five years, will return to the Treasury Department as Senior Vice President-Chief Investment Officer and Treasurer.

Keisha Hutchinson has been named Senior Vice President and Chief Risk Officer, effective June 1, 2021, joining Signature Bank from KPMG. Hutchinson will oversee the Bank's risk management, compliance and information security programs.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT